Shanghai Kaibao Pharmaceutical Asset Resilience Ratio
Shanghai Kaibao Pharmaceutical asset resilience ratio. Shanghai Kaibao Pharmaceutical (300039) has an Asset Resilience Ratio of 5.01% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Shanghai Kaibao Pharmaceutical defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Shanghai Kaibao Pharmaceutical (2014–2025)
Asset resilience ratio of Shanghai Kaibao Pharmaceutical from 2014 to 2025. This chart shows how Shanghai Kaibao Pharmaceutical's Asset Resilience Ratio has changed over time. Read 300039 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Kaibao Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Shanghai Kaibao Pharmaceutical total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥229.99 Million | 5.01% |
| Total Liquid Assets | CN¥229.99 Million | 5.01% |
Asset Resilience Insights
- Limited Liquidity: Shanghai Kaibao Pharmaceutical maintains only 5.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Kaibao Pharmaceutical Industry Peers by Asset Resilience Ratio
Compare Shanghai Kaibao Pharmaceutical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Shanghai Kaibao Pharmaceutical Asset Resilience Ratio by Year (2014–2025)
Shanghai Kaibao Pharmaceutical asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Shanghai Kaibao Pharmaceutical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.22% | CN¥58.53 Million ≈ $8.57 Million |
CN¥4.78 Billion ≈ $699.22 Million |
-2.76pp |
| 2024-12-31 | 3.98% | CN¥180.02 Million ≈ $26.34 Million |
CN¥4.52 Billion ≈ $661.19 Million |
+0.71pp |
| 2023-12-31 | 3.28% | CN¥150.01 Million ≈ $21.95 Million |
CN¥4.58 Billion ≈ $670.15 Million |
+0.08pp |
| 2022-12-31 | 3.19% | CN¥136.07 Million ≈ $19.91 Million |
CN¥4.26 Billion ≈ $623.27 Million |
+1.67pp |
| 2021-12-31 | 1.53% | CN¥51.26 Million ≈ $7.50 Million |
CN¥3.36 Billion ≈ $491.06 Million |
-2.46pp |
| 2020-12-31 | 3.98% | CN¥114.65 Million ≈ $16.78 Million |
CN¥2.88 Billion ≈ $421.04 Million |
-13.10pp |
| 2019-12-31 | 17.08% | CN¥485.57 Million ≈ $71.05 Million |
CN¥2.84 Billion ≈ $415.95 Million |
+14.01pp |
| 2018-12-31 | 3.07% | CN¥84.28 Million ≈ $12.33 Million |
CN¥2.75 Billion ≈ $402.03 Million |
-0.79pp |
| 2017-12-31 | 3.86% | CN¥103.38 Million ≈ $15.13 Million |
CN¥2.68 Billion ≈ $392.13 Million |
+2.21pp |
| 2016-12-31 | 1.64% | CN¥41.58 Million ≈ $6.08 Million |
CN¥2.53 Billion ≈ $369.91 Million |
+0.67pp |
| 2015-12-31 | 0.98% | CN¥23.72 Million ≈ $3.47 Million |
CN¥2.43 Billion ≈ $355.10 Million |
-8.00pp |
| 2014-12-31 | 8.97% | CN¥190.00 Million ≈ $27.80 Million |
CN¥2.12 Billion ≈ $309.84 Million |
-- |
About Shanghai Kaibao Pharmaceutical
Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and… Read more